'bebtelovimab

From Aaushi
Jump to navigation Jump to search
[1][2]

Indications

  • people aged >= 12 years at risk of severe Covid-19

* effective against Omicron variant of SARS CoV2

* bebtelovimab had been used for postexposure prophylaxis in patients at high risk for progression to severe COVID-19.[2]

* currently no FDA-approved post-exposure prophylaxis for people who may have been exposed to COVID-19[2]

More general terms

References

  1. ↑ Reuters staff FDA Okays New Monoclonal Antibody That's Effective Against Omicron. Medscape. Feb 11, 2022 https://www.medscape.com/viewarticle/968390
  2. ↑ 2.0 2.1 2.2 Bronze MS. Rapid Review Quiz: COVID-19 Updates. Medscape. Sep 28, 2022. https://reference.medscape.com/viewarticle/980879
Retrieved from "https://aaushi.info/w/index.php?title=A57493&oldid=1132030"